Novel quinolizidine salicylamide influenza fusion inhibitors

Article abstract of DOI:10.1016/S0960-894X(99)00361-3

A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC₅₀ of 0.25 μg/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed.